aspiration case report semaglutide anesthesia 2023 Elective peri‐operative management of adults taking glucagon‐like peptide‐1 receptor agonists, glucose‐dependent insulinotropic peptide agonists and sodium‐glucose cotransporter‐2 inhibitors: a multidisciplinary consensus statement Popular weight-loss drugs like Wegovy

ABSTRACT INTRODUCTION CURRENT CGM FEATURES RECENT CLINICAL EVIDENCE OF CGM IN PEOPLE WITH DIABETES BENEFITS OF CGM USE IN CLINICAL PRACTICE PRIORITY POPULATIONS FOR CGM IMPLEMENTATION CGM EXPANDABILITY: INTEGRATION WITH VARIOUS INSULIN DELIVERY DEVICES AND MOBILE APPLICATIONS ADVERSE EVENTS ASSOCIATED WITH CGM USE AND MANAGEMENT STRATEGIES IMPORTANCE OF STRUCTURED EDUCATION ON CGM SOCIO-ECONOMIC BURDEN OF CGM CONCLUSION Article information References ABSTRACT Continuous glucose monitoring (CGM) has revolutionized diabetes management, significantly enhancing glycemic control across diverse patient populations

Pennsylvania (Independence Blue Cross) : As of January 1, 2025, IBX restricted Wegovy and Ozempic coverage to FDA-approved conditions (diabetes, heart disease), barring coverage for obesity or weightloss only

Smaller, more frequent meals distribute nutrition throughout the day while avoiding the discomfort of larger portions sitting in a slowly-emptying stomach

In the Phase 2 trial, participants lost up to 24 percent of body weight over 48 weeks at the highest dose

Gmez-Gmez, E et al

Para equiparar potencias tendramos que estar hablando de las dosis de ambos agonistas de Glp-1 que se usan para obesidad: en el caso de liraglutida 3 mg, en el caso de semaglutida 2.4 mg